|Twenty Trading Day Totals|
|Total Shorted Volume||300|
|Total Actual Volume||1,725,049|
|No Change Days||1|
|Average Short Volume||15|
|Average Short Percentage||2.44%|
|Stock Date||Open Price||Close Price||High||Low||Total Volume||Short Volume||Short Percentage|
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
News, Short Squeeze, Breakout and More Instantly...
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and C...
Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volun...
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approv...